Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet ... Gain Therapeutics, Living Cell Technologies, AbbVie, Bluerock, Bayer, and Bial; and receiving honoraria for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback